News
A key advantage of the drug is its oral route of administration, offering patients a more convenient alternative to ...
2h
InvestorsHub on MSNBeOne Medicines shares climb following positive EU backing for lung cancer therapy
BeOne Medicines AG (NASDAQ:ONC) saw its stock rise 2.5% in pre-market trading after the European Medicines Agency (EMA) issued a favorable opinion on its cancer drug TEVIMBRA for early-stage lung ...
The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. LONDON (AP) — The ...
2d
DPA International on MSNEMA recommends approval of additional Alzheimer's treatment
The European Medicines Agency (EMA) cleared the way for the use of another drug to treat Alzheimer's disease on Friday.
Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as ...
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...
Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...
The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.
European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...
Eli Lilly and Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results